Get yourself updated on key emerging technology markets

Know about our market intelligence coverage in key sectors

Product is added to your Wishlist

Global Precision Medicine Market - Estimation and Forecast (2015-2022)

Precision medicine is becoming one of the most modernized trends in the healthcare industry showing an incredible growth in the recent years. The market growth is gaining speed as large number of government initiatives and research & development programs have been launched in the recent years. According to the report put forward by the market research experts of BIS Research, the global precision medicine market is expected to grow over $88 billion by 2022 at an estimated CAGR of 12.60% from 201

SKU: BH002A
Published Year: 2015
 
 

The advancement and innovation of new healthcare technologies are developing the platform for the growth of precision medicine market. Since, the announcement of ‘Precision Medicine Initiative’ by the President Barack Obama in January, 2015, a large number of research and development has been taken for the development of precise drugs, targeted therapeutics, and laboratory tests. Presently, the main focus of the government initiatives is toward oncology, but it is anticipated to target almost all therapeutic areas affected by genetic mutations.
 
Governmental regulations and standards are sustaining the growth and development of the precision medicine market. The main aim of these regulations is to make precision medicines more adaptable and focused towards genetic diseases related to Oncology, skin, respiratory, CNS, CVD, and infectious diseases among others. The patients are benefitted indirectly by these regulations as it save time and cut-down cost as the patients get the required treatment for the specific disease.
 
The growth in the precision medicine market is propelled by an increasing demand for personalized treatment, technological innovation and advancement (including Biomarker-based tests/kits, next gene sequencing, and precise imaging), Government support and regulations, and these have created a demand for the precision medicine solutions.
 
Our study includes an overview and analysis of the precision medicine market by ecosystem, sub-markets, therapeutics and geographical regions, allowing the research to develop a comprehensive outlook of the market. The precision medicine market report presents detailed analysis of the entire precision medicine ecosystem and provides extensive insights of the different developments, trends and key participants. The report also focuses on different sub-markets which help in the development of precision medicine solutions. The sub-market verticals are categorized into five major categories, viz. companion diagnostics, biomarkers, targeted therapeutics, Pharmacogenomics and molecular diagnostics among others in the report.
 
Further, the scope of the report includes the therapeutics of different disease types managed by this technology. All of the above mentioned report coverage parameters are discussed across different regions like The Americas, Europe, Asia Pacific (APAC) and Rest of the World (ROW).
 
While highlighting the key driving and restraining forces for this dynamic market, the report also provides a comprehensive section of the prominent consortiums, compliance, and regulatory bodies and their involvement in the precision medicine market.
 
The answers to the following key questions can be found in the report:

• What are the major market drivers, challenges and opportunities of the precision medicine market and their use cases?

• What are the primary precision medicine market trends and key developments for different precision medicine systems?

• What are the key developmental strategies in different applications across all regions in this market?

• What are different types of precision medicine solutions and the latest precision medicine technologies?

• How will the key market players leverage on key developments such as Mergers and Acquisitions, Partnerships, and Product Launches among others?

• Which geographical region will lead the global precision medicine market by the end of the forecast period?

• Who are the key players in the precision medicine market?

• What kind of government regulations have been implemented for different precision medicine solutions?

• What are the different types of sub-markets in precision medicine market and what are the applications in which they are being used?

• What is the different used case scenarios considered under different applications?

• What are the different therapeutic applications in which precision medicine products are being used?

• What are the precision medicine market trends and key developments in different geographical regions?
 
This research tries to answer various aspects of the precision medicine market such as major factors driving the market, threats that can possibly slow down the market growth, and the current growth opportunities that are going to shape the market expansion of precision medicine solutions. The research study incorporates Porter’s Five Force Model for in-depth analysis of the precision medicine market and an assessment of the factors governing it. The report builds itself upon a comprehensive value chain giving a clear understanding of ecosystem of precision medicine market penetration.
 
Towards the end of the report, the readers will have a clear understanding of the market dynamics, major drivers and the underlying threats and challenges that the global precision medicine industry is subjected to, including the estimation of the industry’s growth in terms of production and revenue.
 
The report includes the profiles of major players in the precision medicine market that allows its readers to get an insight into the industry trends. Some of the leading companies in the precision medicine market are Abbott Laboratories, Almac Group Ltd. and Caris Life sciences among others.

TABLE OF CONTENT
Executive Summary
1 Report scope
1.1 scope of the study
1.2 Precision medicine: report coverage
1.3 BIS RESEARCH METHODOLOGY
1.3.1 Research Methodology for the Global market Study
1.3.1.1 Geographical Analysis
1.3.1.2 Demand Side & Supply Side Analysis
1.3.1.3 Data Synthesis and Bridging
1.3.2 Global Precision medicine: RESEARCH METHODOLOGY
1.3.3 KEY DATA POINT SOURCES
1.3.3.1 Data Points taken from Secondary Sources
1.3.3.2 Data Points taken from Primary Sources
1.4 Report Description
2 Executive Summary
3 Market Overview
3.1 Introduction
3.2 Market Timeline
3.3 KEY PARTICIPANTs, STRATEGIES & DEVELOPMENTS
3.3.1 GOVERNMENT AGENCIES
3.3.2 ACADEMIC INSTITUTIONS
3.3.3 DEVICE & SERVICE PROVIDERS
3.4 KEY MARKET STRATEGIES AND DEVELOPMENTS
3.4.1 INTRODUCTION
3.4.2 Partnerships, Agreements, and collaborations
3.4.3 Mergers & acquisitions
3.4.4 Product Development and Launch
3.4.5 Business Expansion/Contracts
3.4.6 Patents, Approvals and Certifications
3.4.7 Others (Events & Recognitions)
4 Market Dynamics
4.1 Introduction
4.2 Market Drivers
4.2.1 Patients Involvement in personal healthcare
4.2.2 TECHNOLOGIES DRIVING THE MARKET (E.G. Next-Generation Sequencing Technologies, Ultra-High Throughput Sequencing)
4.2.3 Increase in Genetic Diseases
4.2.4 potential for more targeted therapies
4.2.5 Integration of big data healthcare companies with pharma & biotech companies
4.3 Market Challenges
4.3.1 pOTENTIAL THREAT TO Personal data
4.3.2 High diagnostic Cost as a barrier
4.3.3 Potential risk of Hardware or Software failure
4.3.4 Stringent Regulations and Standards
4.3.5 Lack of Awareness about the possible applications of precision medicine
4.3.6 reimbursement policies and regulatory framework
4.3.7 LIMITED KNOWLEDGE ABOUT THE APPLICATION OF TEST AND TECHNIQUES
4.3.8 LACK OF RESEARCH AND EVIDENCES CREATING HINDRANCES IN ITS APPLICATION
4.4 Market Opportunities
4.4.1 Introduction of Precision medicine solutions in developing economies
4.4.2 Downsizing the cost of Genome Sequencing to Three digits
5 Industry Dynamics
5.1 Value Chain Analysis
5.1.1 dEVICE mANUFACTURER & dRUG pRODUCERS
5.1.2 Healthcare Providers
5.1.3 Healthcare ITs or big data companies
5.1.4 Regulators
5.1.5 Third party payers
5.1.6 Patients
5.2 PORTER five FORCE ANALYSIS
5.2.1 Bargaining Power of Buyer (Patient)
5.2.2 Bargaining Power of Supplier
5.2.3 Threat from Substitute
5.2.4 Threat from a New Entrant
5.2.5 Intensity of Competitive Rivalry
6 CONSORTIUMS, CERTIFICATION, REGULATIONS, and  STANDARDS
6.1 Introduction
6.1.1 Regulatory Bodies
6.1.1.1 Food and Drug Administration (FDA)
6.1.1.2 Medicines and Healthcare products Regulatory Agency (MHRA)
6.1.1.3 Therapeutic Goods Administration (TGA)-Australia
6.1.1.4 Conformité Européenne (CE)
6.1.2 Consortiums
6.1.3 Alliances/Associations
7 GLOBAL  PRECISION MEDICINE MARKET BY ECOSYSTEM PLAYERS
7.1 INTRODUCTION
7.1.1 Market Statistics
7.2 Pharmaceuticals and Biotechnology COMPANIES
7.2.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS
7.2.1.1 Market Trends
7.2.1.2 Market Developments
7.2.1.3 Key Participants
7.3 DIAGNOSTIC COMPANIES
7.3.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS
7.3.1.1 Market Trends
7.3.1.2 Market Developments
7.3.1.3 Key Participants
7.4 HEALTHCARE IT SPECIALISTS/ Big Data COMPANIES
7.4.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS
7.4.1.1 Market Trends
7.4.1.2 Market Developments
7.4.1.3 Key Participants
7.5 CLINICAL LABORATORIEs
7.5.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS
7.5.1.1 Regulatory bodies and compliances
7.5.1.2 Market Trends
7.5.1.3 Key Participants
8 GLOBAL PRECISION MEDICINE MARKET BY Sub-markets
8.1 INTRODUCTION
8.1.1 Market Statistics
8.2 COMPANION DIAGNOSTICS
8.3 Biomarker-based Test
8.3.1 Role of Biobanking into biomarker
8.3.2 KEY PARTICIPANTS
8.4 TARGETED THERAPEUTICs
8.4.1 Key Participants
8.5 PHARMACOGENOMICS (PGx)
8.5.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS
8.5.1.1 Market Trends
8.5.1.2 Market Developments
8.5.1.3 Key Participants
8.6 Molecular diagnostics
8.7 Others
8.7.1 Next-Generation Sequencing
8.7.2 CONSUMER GENOMICS
8.7.2.1 Key Participants
8.7.3 3D Printing
8.7.4 Prosthetics Market
8.7.5 Human Tissues Market
9 GLOBAL  PRECISION MEDICINE MARKET BY THERAPEUTICS
9.1 INTRODUCTION
9.1.1 Market Statistics
9.2 CANCER/ONCOLOGY
9.2.1 Market statistics
9.2.2 Types of cancer
9.2.3 Drugs & Tests
9.2.4 Key Market Trends, Developments & Participants
9.2.4.1 Market Trends
9.2.4.2 Market Developments
9.2.4.3 Key Participants
9.3 CARDIOVASCULAR Disease (CVD)
9.3.1 Market Statistics
9.3.2 Drugs & Tests
9.3.3 Market Trends & Market Developments
9.3.3.1 Market trend
9.3.3.2 Market Developments
9.3.3.3 Key Participants
9.4 CENTRAL NERVOUS SYSTEM
9.4.1 Market Statistics
9.4.2 NEUROLOGICAL
9.4.2.1 Neurological Drugs & Tests
9.4.3 PSYCHIATRIC DISORDERS
9.4.3.1 Psychiatric Disorder Drugs & Tests
9.4.4 Market tends & Market Developments
9.4.4.1 Market Trends
9.4.4.2 Key Developments
9.4.4.3 Key Participants
9.5 INFECTIOUS DISEASES
9.5.1 Market Statistics
9.5.2 INFECTIOUS DISEASES DRUGS & TESTS
9.5.3 Market Developments & participants
9.5.3.1 Key Developments
9.5.3.2 Key Participants
9.6 OTHERS
9.6.1 Market Statistics
9.6.2 Market trends, Developments & Participants
9.6.2.1 Market Trends
9.6.2.2 Key Developments
9.6.2.3 Key Participants
10 GLOBAL PRECISION MEDICINE MARKET BY GEOGRAPHY
10.1 INTRODUCTION
10.1.1 MARKET STAtISTICS
10.2 THE AMERICAS
10.2.1 NORTH AMERICA
10.2.1.1 The U.S.
10.2.1.2 Canada
10.2.1.3 Others
10.2.1.4 Key Market Trends, Developments and Participants
10.2.1.5 Regulations and Compliances
10.2.1.6 Market Trends
10.2.1.7 Market Developments
10.2.1.8 Key Participants
10.2.2 SOUTH AMERICA
10.2.2.1 Key Market Trends, Developments and Participants
10.2.2.2 Regulations and Compliances
10.2.2.3 Market Trends
10.2.2.4 Key Participants
10.3 EUROPE
10.3.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS
10.3.1.1 Regulations and Compliances
10.3.1.2 Market Developments
10.3.1.3 Key Participants
10.4 ASIA-PACIFIC (APAC)
10.4.1 Key Market Trends, Developments and Participants
10.4.1.1 Market Developments
10.4.1.2 Key Participants
10.5 Rest of the World/MIDDE EAST & AFRICA (MEA)
10.5.1 Africa
10.5.1.1 Middle East
10.5.2 KEY MARKET DEVELOPMENTS AND PARTICIPANTS
10.5.2.1 Market Developments
10.5.2.2 Key Participants
11 Company Profiles
11.1 ABBOTT LABORATORIES
11.1.1 Overview
11.1.2 Financials
11.1.2.1 Overall Financials
11.1.2.2 Financials by Segment
11.1.2.3 Financials by Region
11.1.2.4 Key Developments
11.1.3 SWOT Analysis
11.2 Almac Group, Ltd.
11.2.1 Overview
11.2.2 Financials
11.2.3 Key Developments
11.2.4 SWOT Analysis
11.3 ASURAGEN, INc.
11.3.1 Overview
11.3.2 Financials
11.3.3 Key Developments
11.3.4 SWOT Analysis
11.4 bioMérieux SA
11.4.1 Overview
11.4.2 Financials
11.4.2.1 Overall Financials
11.4.2.2 Financials By Region
11.4.2.3 Financials By Segment
11.4.3 Key Developments
11.4.4 Swot Analysis
11.5 Cepheid Inc.
11.5.1 Overview
11.5.2 Financials
11.5.2.1 Overall Financials
11.5.2.2 Net Revenue By Segment
11.5.2.3 Net Revenue By Region
11.5.3 Key Developments
11.5.4 SWOT Analysis
11.6 CETICS Healthcare Technologies GmbH
11.6.1 Overview
11.6.2 Financials
11.6.3 Key Developments
11.6.4 SWOT Analysis
11.7 GE Healthcare
11.7.1 overview
11.7.2 Financials
11.7.2.1 Overall Financials
11.7.2.2 Net Revenue By Segment
11.7.2.3 Financial Summary
11.7.3 Key Developments
11.8 Glaxosmithkline Plc (GSK)
11.8.1 Overview
11.8.2 Financials
11.8.2.1 Overall Financials
11.8.2.2 Financials By Segment
11.8.2.3 Financials By Region
11.8.2.4 Financials By Therapeutics
11.9 Intomics A/S
11.9.1 Overview
11.9.2 Financials
11.9.3 Key Developments
11.9.4 SWOT Analysis
11.1 Johnson & Johnson
11.10.1 Overview
11.10.2 Financials
11.10.2.1 Overall Financials
11.10.2.2 Net Revenue By Segment
11.10.2.3 Net revenue by Region
11.10.3 Key Developments
11.11 LABORATORY CORPORATION OF AMERICA HOLDINGS
11.11.1 Overview
11.11.2 Financials
11.11.2.1 Overall Financials
11.11.2.2 Financials by Segment
11.11.3 Key Developments
11.11.4 SWOT Analysis
11.12 Medtronic
11.12.1 Overview
11.12.2 Financials
11.12.2.1 Overall Financials
11.12.3 Key Developments
11.13 Novartis
11.13.1 Overview
11.13.2 Financials
11.13.2.1 Overall Financials
11.13.2.2 Financials By Region
11.13.2.3 Financials By Segment
11.14 Pfizer Inc.
11.14.1 Overview
11.14.2 Financials
11.14.2.1 Overall Financials
11.14.2.2 Net Revenue By Segment
11.14.2.3 Net Revenue By Region
11.14.3 Key Developments
11.14.4 Swot analysis
11.15 Qiagen
11.15.1 Overview
11.16 BIOBASE GmbH (Subsidiary)
11.16.1 Overview
11.16.2 Financials
11.16.2.1 Overall Financials
11.16.3 Key Developments (BIOBASE)
11.17 Quest Diagnostics Inc
11.17.1 Overview
11.17.2 Financials
11.17.2.1 Overall Financials
11.17.2.2 Net Revenue By Segment
11.17.3 Key Developments
11.17.4 SWOT Analysis
11.18 Randox Laboratories Ltd.
11.18.1 Overview
11.18.2 Financials
11.18.3 Key Developments
11.18.4 SWOT Analysis
11.19 Roche Holding AG-Br
11.19.1 Overview
11.19.2 Financials
11.19.2.1 Overall Financials
11.19.2.2 Net Revenue By Segment
11.19.3 Key Developments
11.19.4 SWOT Analysis
11.2 Sanofi Pharma
11.20.1 Overview
11.20.2 Financials
11.20.2.1 Overall Financials
11.20.2.2 Net Revenue By Segment
11.21 Takeda Pharmaceutical Company Limited
11.21.1 Overview
11.21.2 Financials
11.21.2.1 Overall Financials
11.21.3 Key Developments
11.21.4 SWOT Analysis
11.22 Teva Pharmaceutical Industries Ltd.
11.22.1 Overview
11.22.2 Financials
11.22.2.1 Overall Financials
11.22.2.2 Net Revenue By Segment
11.22.2.3 Net Revenue By Segment
11.22.3 Key Developments
11.22.4 SWOT Analysis
11.23 AB-Biotics SA
11.23.1 Overview
11.24 Caris Life Sciences
11.24.1 Overview
11.25 HealthCore, Inc.
11.25.1 Overview
11.26 IBM
11.26.1 Overview
11.27 InnVentis
11.27.1 Overview
11.28 Intel Corporation
11.28.1 Overview
11.29 Molecular Health GmbH
11.29.1 Overview
11.3 Precision for Medicine
11.30.1 Overview
List of Tables
TABLE 1 leading companies in the precision medicine market
TABLE 2 Downsizing cost of Genome Sequencing
TABLE 3 Factors impacting the buyer’s bargaining power
TABLE 4 Factors impacting the supplier’s bargaining power
TABLE 5 Factors Impacting the Threat from substitute
TABLE 6 Factors Impacting the Threat from New Entrant
TABLE 7 Factors Impacting the Degree of Competition
TABLE 8 Regulatory bodies in precision medicine market
TABLE 9 CONSORTIUMS in precision medicine market
TABLE 10 ALLIANCES/ASSOCIATIONSin precision medicine market
TABLE 11 Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Billion)
TABLE 12 Pharma & biotech: Global Precision Medicine Market Value, By Sub-market types, 2014-2022 ($Billion)
TABLE 13 Pharma & biotech: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($Billion)
TABLE 14 Pharma & biotech: Global Precision Medicine Market Value, By Geography, 2014-2022 ($Billion)
TABLE 15 Key developments in Pharma & Biotech companies(2015)
TABLE 16 diagnostic tools: Global Precision Medicine Market Value, By Sub-market types, 2014-2022 ($Billion)
TABLE 17 diagnostic tools: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($Billion)
TABLE 18 diagnostic tools: Global Precision Medicine Market Value, By Geography, 2014-2022 ($Billion)
TABLE 19 Key developments in Diagnostic companies(2015)
TABLE 20 Healthcare its/big data: Global Precision Medicine Market Value, By Sub-market types, 2014-2022 ($Billion)
TABLE 21 Healthcare its/big data: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($Billion)
TABLE 22 Healthcare its/big data: Global Precision Medicine Market Value, By Geography, 2014-2022 ($Billion)
TABLE 23 Key Developments in HEalthcare IT/Big data companies(2015)
TABLE 24 Clinical Laboratories: Global Precision Medicine Market Value, By Sub-market types, 2014-2022 ($Billion)
TABLE 25 Clinical Laboratories: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($Billion)
TABLE 26 Clinical Laboratories: Global Precision Medicine Market Value, By Geography, 2014-2022 ($Billion)
TABLE 27 Global Precision Medicine Market Value, By Sub-market types, 2014-2022 ($Billion)
TABLE 28 Companion diagnostics: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($million)
TABLE 29 Companion diagnostics: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($million)
TABLE 30 List of Approved Companion Diagnostic Devices
TABLE 31 biomarker: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($million)
TABLE 32 biomarker: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($million)
TABLE 33 List of biobanks
TABLE 34 Examples of biobanking initiatives across  selected OECD countries
TABLE 35 Targeted Therapeutics: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($million)
TABLE 36 Targeted Therapeutics: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($million)
TABLE 37 pharmacogenomics: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($million)
TABLE 38 pharmacogenomics: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($million)
TABLE 39 molecular diagnostics: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($million)
TABLE 40 molecular diagnostics: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($million)
TABLE 41 other sub-markets: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($million)
TABLE 42 other sub-markets: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($million)
TABLE 43 Global Precision Medicine Market Value, By Therapeutic Applications, 2014-2022 ($Billion)
TABLE 44 Cancer: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Billion)
TABLE 45 Cancer: Global Precision Medicine Market Value, By Sub-market types, 2014-2022 ($Billion)
TABLE 46 Cancer: Global Precision Medicine Market Value, By Geography, 2014-2022 ($Billion)
TABLE 47 Precision MEDICINE DRUGS AND RELEVANT GENES: Oncology
TABLE 48 Precision MEDICINE GENETIC TESTS WITH RESPECT TO Oncology
TABLE 49 Key Developments (2013-2015)
TABLE 50 Cvd: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Billion)
TABLE 51 Cvd: Global Precision Medicine Market Value, By Sub-market types, 2014-2022 ($Billion)
TABLE 52 Cvd: Global Precision Medicine Market Value, By Geography, 2014-2022 ($million)
TABLE 53 Precision MEDICINE DRUGS AND RELEVANT GENES: Cardiovascular
TABLE 54 Precision MEDICINE GENETIC TESTS WITH RESPECT TO Cardiovascular
TABLE 55 Key Developments (2014-2015)
TABLE 56 Cns: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($million)
TABLE 57 Cns: Global Precision Medicine Market Value,  By Sub-market types, 2014-2022 ($million)
TABLE 58 Cns: Global Precision Medicine Market Value, By Geography, 2014-2022 ($million)
TABLE 59 Precision MEDICINE DRUGS AND RELEVANT GENES: Neurology
TABLE 60 Precision MEDICINE DRUGS AND RELEVANTGENES: Psychiatric DISORDERS
TABLE 61 Precision MEDICINE GENETIC TESTS WITH RESPECT TO PSYCHIATRIC DISORDERS
TABLE 62 PSYCHIATRIC DISORDERS: Key Developments (2014-2015)
TABLE 63 infectious disease: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($million)
TABLE 64 infectious disease: Global Precision Medicine Market Value, By Sub-market types, 2014-2022 ($million)
TABLE 65 infectious disease: Global Precision Medicine Market Value, By Geography, 2014-2022 ($million)
TABLE 66 Precision MEDICINE DRUGS AND RELEVANT GENES: infectious Diseases
TABLE 67 other therapeutics: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($million)
TABLE 68 other therapeutics: Global Precision Medicine Market Value, By Sub-market types, 2014-2022 ($million)
TABLE 69 other therapeutics: Global Precision Medicine Market Value, By Geography, 2014-2022 ($million)
TABLE 70 Precision MEDICINE DRUGS AND RELEVANT GENES: Other Diseases
TABLE 71 Precision MEDICINE GENETIC TESTS WITH RESPECT TO other diseases
TABLE 72 Global Precision Medicine Market Value, By Geography, 2014-2022 ($Billion)
TABLE 73 americas: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($billion)
TABLE 74 americas: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($billion)
TABLE 75 americas: Global Precision Medicine Market Value, By Therapeutic Applications, 2014-2022 ($billion)
TABLE 76 europe: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($billion)
TABLE 77 europe: Global Precision Medicine Market Value, By Therapeutic Applications, 2014-2022 ($billion)
TABLE 78 apac: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($billion)
TABLE 79 apac: Global Precision Medicine Market Value, By Therapeutic Applications, 2014-2022 ($million)
TABLE 80 ROW: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($million)
TABLE 81 ROW: Global Precision Medicine Market Value, By Therapeutic Applications, 2014-2022 ($million)
List of Figures
FIGURE 1 Precision medicine market study
FIGURE 2 BIS Research Methodology
FIGURE 3 Different phases of research methodology for the Global market
FIGURE 4 precision medicine Market: research methodology
FIGURE 5 Global PRECISION MEDICINE market share, by ecosystem, 2014-2022 ($billion)
FIGURE 6 Global PRECISION MEDICINE market Size, by Sub-market Type, 2014 – 2022 (billion)
FIGURE 7 Global PRECISION MEDICINE market Size, by Therpeutic application, 2014 – 2022 (billion)
FIGURE 8 Global Precision medicine market Size, by Geography, 2014 – 2022 ($Billion)
FIGURE 9 Timeline of Precision Medicine
FIGURE 10 Precision Medicine: Benefits
FIGURE 11 Examples: Applied areas of Precision Medicine
FIGURE 12 Elements of Precision Medicine Technology
FIGURE 13 Different Type of Data used by big data companies
FIGURE 14 Precision Medicine : Areas of Interest
FIGURE 15 precision medicine: Partnerships, Agreements, and collaborations (2015)
FIGURE 16 precision medicine : mergers & Acquisitions( 2015)
FIGURE 17 precision medicine: Key Product Launch & Developments (2015)
FIGURE 18 precision medicine: Key Business Expansions & Contracts (2015)
FIGURE 19 precision medicine : Key Patents/ Approvals ( 2015)
FIGURE 20 precision medicine: EVENTS & Recognition (2015)
FIGURE 21 Market drivers and challenges
FIGURE 22 Benefits of precision medicine to patients
FIGURE 23 Major barriers caused by regulation and standards
FIGURE 24 Flow Chart of Precision Medicine
FIGURE 25 Precision medicine Market: Porter Five Force Analysis
FIGURE 26 Roles and Responsibilities of healthcare Policy makers
FIGURE 27 Role of FDA in Precision Medicine
FIGURE 28 classification of medical devices
FIGURE 29 GLOBAL  PRECISION MEDICINE MARKET BY ECOSYSTEM PLAYERS
FIGURE 30 Role of Pharmaceuticals and Biotech Companies
FIGURE 31 Challenges faced by Pharma & Biotech Companies
FIGURE 32 diagnostic tests Benefits for Stakeholders
FIGURE 33 Challenges Faced by diagnostic companies
FIGURE 34 Benefits of Big data
FIGURE 35 Transformation of medicine
FIGURE 36 basic ingredients provided by big data for Precision Medicine
FIGURE 37 Challenges faced by Big Data Companies
FIGURE 38 OECD recommendations on the governance of clinical trials
FIGURE 39 Types of precision medicine Sub-market
FIGURE 40 Benefits of Companion Diagnostics
FIGURE 41 Function of Biomarkers
FIGURE 42 Biobanks Services
FIGURE 43 Development in PGx
FIGURE 44 Model Systems used in PGx
FIGURE 45 Challenges of PGx Studies
FIGURE 46 Figure Title Missing
FIGURE 47 Molecular diagnostics: Application
FIGURE 48 Molecular diagnostics: Benefits
FIGURE 49 Global Precision Medicine Market: By Therapeutics
FIGURE 50 Target Scope of Precision Medicine By Cancer types
FIGURE 51 Global precision medicine Market classification, By Geography
FIGURE 52 Key Drivers For Precision Medicine: North America
FIGURE 53 Objectives of the Precision Medicine Initiative
FIGURE 54 APAC: Market Challenges
FIGURE 55 Abbott: overall financials ($Billion), 2012-2014
FIGURE 56 Abbott: Net revenue by segments ($Billion), 2012-2014
FIGURE 57 Abbott: Net revenue by Region, 2012-2014 ($Billion)
FIGURE 58 Abbott: SWOT Analysis
FIGURE 59 Almac: SWOT Analysis
FIGURE 60 Asuragen: SWOT Analysis
FIGURE 61 Biomerieux: overall financials ($Million), 2012-2014
FIGURE 62 Biomerieux: Net Revenue By Region, 2014
FIGURE 63 Biomerieux: Net Revenue by Segment, 2014
FIGURE 64 Biomerieux: SWOT Analysis
FIGURE 65 CEpheid: overall financials, 2012-2014 ($Million)
FIGURE 66 CEpheid: Net REVENUE, BY segments, 2012-2014 ($million)
FIGURE 67 CEpheid: Net REVENUE, BY Region, 2012-2014 ($million)
FIGURE 68 CEPheid: SWOT Analysis
FIGURE 69 CETICS Healthcare: SWOT Analysis
FIGURE 70 GE Corporation: overall Financials, 2012-2014 ($Billion)
FIGURE 71 GE Corporation: Net revenue, by segments, 2012-2014 ($million)
FIGURE 72 GE Corporation: Healthcare Segment, 2014
FIGURE 73 GSK: Overall Financials, 2012-2014 ($Billion)
FIGURE 74 GSK: Net Revenue By Segment, 2014 ($Billion)
FIGURE 75 GSK: Net Revenue By Region, 2014 ($Billion)
FIGURE 76 GSK: Net Revenue By Therapeutics, 2014 ($Billion)
FIGURE 77 Intomics: SWOT Analysis
FIGURE 78 J&J: Overall Financials, 2012 - 2014 ($Billion)
FIGURE 79 J&J: Net revenue by segment, 2012 - 2014 ($Million)
FIGURE 80 J&J: Net revenue by Region, 2012 - 2014 ($million)
FIGURE 81 Labcorp: overall financials ($Million), 2012-2014
FIGURE 82 Net revenue by segments, 2012-2014 ($Million)
FIGURE 83 LABCORP: SWOT Analysis
FIGURE 84 Medtronic: Overall Financials, 2012 - 2014 ($Million)
FIGURE 85 Novartis: Overall Financials, 2012 - 2014 ($Billion)
FIGURE 86 Novartis: Net Revenue By region, 2014 ($Billion)
FIGURE 87 Novartis: Net Revenue By Segment, 2014 ($Billion)
FIGURE 88 Pfizer: Overall Financials, 2012 – 2014 ($Billion)
FIGURE 89 Pfizer: NET REVENUE, BY SEGMENT, 2012-2014 ($Million)
FIGURE 90 Pfizer: NET REVENUE, BY REGION, 2012-2014 ($Billion)
FIGURE 91 pfizer: Swot analysis
FIGURE 92 Qiagen: overall financials ($Million), 2012-2014
FIGURE 93 Qiagen: Net Revenue By Region ($Million), 2014
FIGURE 94 Qiagen: Net Revenue By Segment, 2014
FIGURE 95 Quest: Overall Financials, 2012 - 2014 ($Million)
FIGURE 96 Quest: Net revenue, by segment, 2012 - 2014 ($million)
FIGURE 97 Quest: SWOT Analysis
FIGURE 98 Randox: SWOT Analysis
FIGURE 99 Roche: overall financials, 2012-2014 ($Billion)
FIGURE 100 Roche: Net revenue, by segments, 2012-2014 ($Billion)
FIGURE 101 ROCHE: SWOT Analysis
FIGURE 102 Sanofi Pharma: overall financials, 2012-2014($Billion)
FIGURE 103 Sanofi Pharma: Net REVENUE, BY Segments, 2012-2014 ($Bilion)
FIGURE 104 Takeda: Overall Financials, 2012-2014 ($Billion)
FIGURE 105 Takeda: SWOT Analysis
FIGURE 106 Teva: Overall Financials, 2012 – 2014 ($Billion)
FIGURE 107 TEVA: Net revenue Share, by segment (2014)
FIGURE 108 TEVA: Net revenue Share, by Region (2014)
FIGURE 109 Teva: SWOT Analysis

Precision medicine is becoming one of the most modernized trends in the healthcare industry showing an incredible growth in the recent years. The market growth is gaining speed as large number of government initiatives and research & development programs have been launched in the recent years. According to the report put forward by the market research experts of BIS Research, the global precision medicine market is expected to grow over $88 billion by 2022 at an estimated CAGR of 12.60% from 2015 to 2022.

While The Americas will continue to lead the global market through the forecast period, Europe and APAC will continue to be the principal revenue generating countries of the world. The global precision medicine market, on the basis of sub-market categories, is segmented into: companion diagnostics, biomarkers, targeted therapeutics, pharmacogenomics, molecular diagnostics and others. With increasing research and development processes, it has been estimated that the demand for precision drugs will escalate in the coming future, thus, resulting in the domination of the Pharma & Biotech segment. At present, Cancer is dominating the market and is expected to reach $46.38 billion by 2022, as the number of cancer patients are increasing every year and thus, deployment of targeted therapeutics and diagnosis applications of cancer is also anticipated to increase tremendously.

Primarily, the reason attributed to the growth of the precision medicine therapeutics market is due to the increase in cancer cases, cardiac diseases, skin diseases, mental disorders, and other gene related issues. In Americas have existing players who are integrating with new start-ups through partnerships and collaboration so as to capture the North American segment. North American local players are entering to capture the South American precision medicine market. Throughout the Asia-Pacific countries, regulatory bodies are rolling out regulations to keep a check on latest technologies.

We understand that your business need specific answers pertaining to the market. And , therefore, we do provide customised research tailored to your need.

With the purchase of this report, you are entitled to certain degree of free customisation within the scope of the study.

Do get in touch to help us understand how we can serve u better with a custom solution to your research needs. We assure quick turnaround for your pressing business requirements.

Contact Information


Name *
Email *
 
Company Name *
Designation
 
 
Contact No. *
Other Details
 
 

Write the characters in the image above
 
 
* Required Fields

OUR HAPPY CLIENTS


related reports

 

OUR CLIENTS